Zymeworks Inc
Change company Symbol lookup
Select an option...
ZYME Zymeworks Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
JNJ Johnson & Johnson
SCHD Schwab U.S. Dividend Equity ETF™
PAYS Paysign Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
Go

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Closing Price
$6.15
Day's Change
0.34 (5.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.26
Day's Low
5.80
Volume
(Heavy Day)
Volume:
696,590

10-day average volume:
517,410
696,590

Display:

Providers:

UpdateCancel
4 providers
May 29, 2022
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

Jaimy Lee Arcellx shares surged, while Iovance Biotherapeutics and SpringWorks lost more than half their value The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers...(MarketWatch)

May 20, 2022
Zymeworks rejects 'unsolicited, opportunistic' buyout bid by UAE-based All Blue Falcons

Shares of Zymeworks Inc. (ZYME) rallied 1.5% in morning trading Friday, after the biopharmaceutical company said it rejected the "unsolicited, opportunistic, non-binding" $10.50-per-share buyout bid by activist investor All Blue Falcons FZE...(MarketWatch)

April 13, 2022
Zymeworks stock price target cut to $18 from $32 at J.P. Morgan

(END) Dow Jones Newswires April 13, 2022 07:06 ET (11:06 GMT) (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.